-
11.发明公开USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES IN THE PREVENTION AND THERAPY OF ATHEROSCLEROTIC DEGRADATION OF ARTERIAL WALLS 失效1,4-二氢吡啶衍生物的动脉壁中动脉粥样硬化变性的预防和治疗
公开(公告)号：EP0839036A1
公开(公告)日：1998-05-06
申请号：EP96924834.0
申请日：1996-06-28
申请人： RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY , RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
CPC分类号： A61K31/4422 , A61K31/4439
摘要： 1,4-Dihydropyridines have been found to counter several processes which play a role in the development of atherosclerotic vascular lesions, such as myocytes proliferation and migration, cholesterol metabolism in macrophages and oxidative modification of low density lipoproteins. They are therefore useful in the manufacture of medicaments for preventing, arresting and reversing atherosclerotic degradation in the arterial walls of humans. The preferred 1,4-dihydropyridines for this purpose are lercanidipine, (S)-lercanidipine and (R)-lercanidipine.
-
公开(公告)号：EP0824517A1
公开(公告)日：1998-02-25
申请号：EP96916111.0
申请日：1996-05-09
申请人： RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY , RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
发明人： LEONARDI, Amedeo , MOTTA, Gianni
IPC分类号： C07D211
CPC分类号： C07D211/90
摘要： A process for the preparation of methyl 1,1,N-trimethyl-N-(3,3-diphenyl-propyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (lercanidipine) of formula I comprises reacting an acid halide of 2,6-dimethyl-5-methoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid with 2,N-dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol in an aprotic solvent. The product can be isolated by industrially applicable crystallization techniques and is obtained in high yield as its anhydrous hydrochloride, a form which possesses high stability and low hygroscopicity.
-
13.发明公开
公开(公告)号：EP0769948A1
公开(公告)日：1997-05-02
申请号：EP95918125.0
申请日：1995-05-29
申请人： RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. , RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY
CPC分类号： A61K9/0095 , A61K9/5073 , A61K31/426
摘要： Disclosed are compositions and dosage forms containing moguisteine and having controlled release properties, methods for using such compositions and dosage forms and methods for making them.
-
14.发明公开Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors 失效Heterobicyclische Verbindungen als Alpha-1-Adrenergene und 5HT1A-Rezeptor-Antagonisten。
公开(公告)号：EP0558245A1
公开(公告)日：1993-09-01
申请号：EP93301264.3
申请日：1993-02-22
申请人： RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY , RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
发明人： Leonardi, Amedeo , Motta, Gianni , Riva, Carlo , Testa, Rodolfo
IPC分类号： C07D311/30 , C07D407/12 , C07D405/12 , C07D405/14 , C07D311/22 , C07D407/04 , C07D409/04 , C07D335/06 , C07D405/04 , C07D307/79 , C07F9/655 , A61K31/35
CPC分类号： C07D307/79 , C07D307/80 , C07D311/22 , C07D311/30 , C07D311/32 , C07D311/60 , C07D335/06 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/04 , C07F9/65586
摘要： There are disclosed compounds of the general formula
The heteroatom X is preferably oxygen, but may have other values. The group W is preferably a carbonyl group, but may have other values. The preferred heterocyclic ring is thus a 4-oxo-4H-1-benzopyran ring. This may have a wide range of R₂, R₃, R₆ and R₇ substituents. Y is a linking group, chosen from a wide range, but including -COO- , -CONH- , -O- , -SO₂- and -SO₂NH-. Z is an alkylene chain, and B is a complex amine. These compounds and their prodrugs, enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts are useful for the treatment of hypertension and urinary tract troubles associated with benign prostatic hypertrophy, and for the treatment of other diseases.摘要翻译： 公开了通式
的化合物。杂原子X优选为氧，但可具有其它值。 基团W优选为羰基，但可以具有其它值。 因此优选的杂环是4-氧代-4H-1-苯并吡喃环。 这可以具有宽范围的R2，R3，R6和R7取代基。 Y是选自宽范围的但包括-COO - ， - CONH - ， - O - ， - SO 2 - 和-SO 2 NH-的连接基团。 Z是亚烷基链，B是复合胺。 这些化合物及其前药，对映异构体，非对映异构体，N-氧化物和药学上可接受的盐可用于治疗与良性前列腺肥大相关的高血压和尿路麻烦以及治疗其它疾病。 -
公开(公告)号：EP0250374B1
公开(公告)日：1991-05-02
申请号：EP87830223.1
申请日：1987-06-15
发明人： La Manna, Aldo , Colombo, Paolo , Gazzaniga, Andrea , Santus, Giancarlo , Conte, Ubaldo , Sangalli, Maria Edvige
CPC分类号： A61K9/1652 , A61K9/1635 , A61K9/5026
-
公开(公告)号：EP3572068A1
公开(公告)日：2019-11-27
申请号：EP18425038.9
申请日：2018-05-22
IPC分类号： A61K9/00 , A61K45/06 , A61K31/145 , A61K9/16 , A61P11/12
摘要： The present invention provides inhalable microparticles comprising cysteamine hyaluronate salt. Also a preparation method and a pharmaceutical composition thereof are provided.
-
公开(公告)号：EP1856051B1
公开(公告)日：2019-11-13
申请号：EP06723128.2
申请日：2006-02-24
发明人： LEONARDI, Amedeo , MOTTA, Gianni , BERLATI, Fabio
IPC分类号： C07D211/90 , A61K31/435 , A61P9/12
-
18.发明公开SERTRALINE HYDROCHLORIDE FORM II AND METHODS FOR THE PREPARATION THEREOF 审中-公开SERTRALIN HYDROCHLORID FORM II UND VERFAHREN ZU SEINER HERSTELLUNG
公开(公告)号：EP1646605A1
公开(公告)日：2006-04-19
申请号：EP04766217.6
申请日：2004-07-14
IPC分类号： C07C209/84 , C07C211/42
CPC分类号： C07C211/42 , C07C209/84 , C07C2602/10
摘要： This invention relates to a method for the preparation of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, in its crystalline form II.
摘要翻译： 本发明涉及盐酸舍曲林（1S-顺式）-4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺盐酸盐的制备方法 晶型II。
-
19.发明授权USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION 有权选择性α肾上腺素能受体拮抗剂对性疾病的治疗用途
公开(公告)号：EP1177190B1
公开(公告)日：2005-11-02
申请号：EP00927199.0
申请日：2000-05-08
IPC分类号： C07D403/04 , C07D407/14 , A61K31/517 , A61P15/10
CPC分类号： C07D403/04 , A61K31/517 , A61K31/519 , A61K31/557 , A61K45/06 , C07D239/95 , C07D405/12 , C07D405/14 , G01N33/9433 , G01N2500/00 , A61K2300/00
摘要： Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the alpha1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.
-
20.发明公开
公开(公告)号：EP1432701A1
公开(公告)日：2004-06-30
申请号：EP02782863.1
申请日：2002-10-07
申请人： RECORDATI S.A.CHEMICAL and PHARMACEUTICAL COMPANY , RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
IPC分类号： C07D401/12 , A61K31/47 , A61K31/404 , A61P13/00 , C07D215/12 , C07D215/18 , C07D215/20 , C07D405/12 , C07D215/40 , C07D215/42 , C07D215/26 , C07D401/06 , C07D417/12 , C07D413/12 , C07D409/08 , C07D413/08 , C07D401/14 , C07D405/14 , C07D413/14 , C07D409/14
CPC分类号： C07D401/06 , C07D215/12 , C07D215/18 , C07D215/20 , C07D215/26 , C07D215/40 , C07D215/42 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/08 , C07D409/14 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Compounds of formula (I) are thus useful for treating disorders of the urinary tract. In the compounds I, R1 = one or more substituents selected from H, halogen, OH, alkyl, haloalkyl, alkoxy, haloalkoxy, NO2, nitro, phenyl, substituted phenyl, heterocycle, substituted heterocycle, NR3R4(R3 and R4 being H, alkyl, acyl or alkoxycarbonyl); R2 = one or two substituents selected from H, alkyl; Y = CH2 or a bond; Q = CO, CS or SO2; A = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkylamino, dialkylamino, arylamino or arylalkylamino, each of which is optionally substituted; n is 1 or 2; X = an amino moiety selected from formula (a), (b) and -N(R5)-CH2-(R5 = H, methyl, benzyl group; W = bond, N, CH, CH2, C(CN) C(OH) or C(COCH3) (when W represents a nitrogen atom or a CH, C(CN) C(OH) or C(COCH3) group, the group Z-B attaches to the W ring atom); when X is (a) or (b), Z = bond, O, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO or NHCONHCH2, but when X is -N(R5)-CH2-group, Z represents a CH2CH2 or CH2O group or Z and B together represent a 2,3-dihydro-benzo[1,4]dioxin-2-yl group; and B is a monocyclic or bicyclic aryl group or a monocyclic or bicyclic heterocycle, each of which is optionally substituted.
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.017 秒)
